Antitumor activity of miR-1280 in melanoma by regulation of Src

Molecular Therapy

Volumn 23, Issue 1, 2015, Pages 71-78

  Sun, Vera ^a   Zhou, Wen B ^a   Nosrati, Mehdi ^a   Majid, Shahana ^b   Thummala, Suresh ^a   De Semir, David ^a   Bezrookove, Vladimir ^a   De Feraudy, Sebastien ^a   Chun, Liane ^a   Schadendorf, Dirk ^c   Debs, Robert ^a   Kashani Sabet, Mohammed ^a   Dar, Altaf A ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; MICRORNA; MICRORNA 1280; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; LUCIFERASE; PROTEIN KINASE P60;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL INVASION; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL LINE; MOUSE; NEVUS; NONHUMAN; ONCOGENE SRC; PLASMID; ANIMAL; CELL CYCLE; CELL MOTION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; PROMOTER REGION; REPORTER GENE; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LUCIFERASES; MELANOMA; MICE; MICE, NUDE; MICRORNAS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS PP60(C-SRC); SIGNAL TRANSDUCTION; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920685408     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.176     Document Type: Article

References (41)

1. Siegel, R, Ward, E, Brawley, O and Jemal, A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Sharpless, E and Chin, L (2003). The INK4a/ARF locus and melanoma. Oncogene 22: 3092-3098.
3. Davies, H, Bignell, GR, Cox, C, Stephens, P, Edkins, S, Clegg, S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
4. Miranda, KC, Huynh, T, Tay, Y, Ang, YS, Tam, WL, Thomson, AM et al. (2006). A pattern-based method for the identifcation of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126: 1203-1217.
5. Ambros, V and Chen, X (2007). The regulation of genes and genomes by small RNAs. Development 134: 1635-1641.
6. He, L and Hannon, GJ (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531.
7. Sempere, LF, Freemantle, S, Pitha-Rowe, I, Moss, E, Dmitrovsky, E and Ambros, V (2004). Expression profling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 5: R13.
8. Bartel, DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
9. Medina, PP, Nolde, M and Slack, FJ (2010). OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467: 86-90.
10. Obad, S, dos Santos, CO, Petri, A, Heidenblad, M, Broom, O, Ruse, C et al. (2011). Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43: 371-378.
11. Saito, Y, Liang, G, Egger, G, Friedman, JM, Chuang, JC, Coetzee, GA et al. (2006). Specifc activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443.
12. Lujambio, A, Ropero, S, Ballestar, E, Fraga, M F, Cerrato, C, Setién, F et al. (2007). Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67: 1424-1429.
13. Lujambio, A, Calin, GA, Villanueva, A, Ropero, S, Sánchez-Céspedes, M, Blanco, D et al. (2008). A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105: 13556-13561.
14. Yi, R and Fuchs, E (2010). MicroRNA-mediated control in the skin. Cell Death Differ 17: 229-235.
15. Bartels, CL and Tsongalis, GJ (2009). MicroRNAs: novel biomarkers for human cancer. Clin Chem 55: 623-631.
16. Kim, LC, Song, L and Haura, EB (2009). Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6: 587-595.
17. Irby, RB and Yeatman, TJ (2000). Role of Src expression and activation in human cancer. Oncogene 19: 5636-5642.
18. Kumble, S, Omary, MB, Cartwright, CA and Triadaflopoulos, G (1997). Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterology 112: 348-356.
19. Aligayer, H, Boyd, DD, Heiss, MM, Abdalla, EK, Curley, SA and Gallick, GE (2002). Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94: 344-351.
20. Trevino, JG, Summy, JM, Lesslie, DP, Parikh, NU, Hong, DS, Lee, FY et al. (2006). Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 168: 962-972.
21. Homsi, J, Cubitt, C and Daud, A (2007). The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets 11: 91-100.
22. Buettner, R, Mesa, T, Vultur, A, Lee, F and Jove, R (2008). Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 6: 1766-1774.
23. Niu, G, Bowman, T, Huang, M, Shivers, S, Reintgen, D, Daud, A et al. (2002). Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21: 7001-7010.
24. Wheeler, DL, Iida, M and Dunn, EF (2009). The role of Src in solid tumors. Oncologist 14: 667-678.
25. Majid, S, Dar, AA, Saini, S, Arora, S, Shahryari, V, Zaman, MS et al. (2012). miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic signifcance in prostate cancer. Cancer Res 72: 6435-6446.
26. Courtneidge, SA, Fumagalli, S, Koegl, M, Superti-Furga, G, and Twamley-Stein, GM (1993). The Src family of protein tyrosine kinases: regulation and functions. Development (Cambridge, England): 57-64.
27. Barnekow, A, Paul, E and Schartl, M (1987). Expression of the c-src protooncogene in human skin tumors. Cancer Res 47: 235-240.
28. Majid, S, Dar, AA, Saini, S, Shahryari, V, Arora, S, Zaman, MS et al. (2012). MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One 7: e46743.
29. Lee, JH, Pyon, JK, Kim, DW, Lee, SH, Nam, HS, Kim, CH et al. (2010). Elevated c-Src and c-Yes expression in malignant skin cancers. J Exp Clin Cancer Res 29: 116.
30. Homsi, J, Cubitt, CL, Zhang, S, Munster, PN, Yu, H, Sullivan, DM et al. (2009). Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res 19: 167-175.
31. Asangani, IA, Harms, PW, Dodson, L, Pandhi, M, Kunju, LP, Maher, CA et al. (2012). Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 3: 1011-1025.
32. Duxbury, MS, Ito, H, Zinner, MJ, Ashley, SW and Whang, EE (2004). Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 10: 2307-2318.
33. Jallal, H, Valentino, ML, Chen, G, Boschelli, F, Ali, S and Rabbani, SA (2007). A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 67: 1580-1588.
34. Masaki, T, Igarashi, K, Tokuda, M, Yukimasa, S, Han, F, Jin, YJ et al. (2003). pp60c-src activation in lung adenocarcinoma. Eur J Cancer 39: 1447-1455.
35. Gangadhar, TC, Clark, JI, Karrison, T, and Gajewski, TF (2013). Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs 31: 769-773.
36. Kortylewski, M, Jove, R and Yu, H (2005). Targeting STAT3 affects melanoma on multiple fronts. Cancer Metast Rev 24: 315-327.
37. Dummer, R, Rochlitz, C, Velu, T, Acres, B, Limacher, JM, Bleuzen, P et al. (2008). Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther 16: 985-994.
38. Kaufman, HL, Kim, DW, DeRaffele, G, Mitcham, J, Coffn, RS, and Kim-Schulze, S (2010). Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17: 718-730.
39. Weide, B, Derhovanessian, E, Pfugfelder, A, Eigentler, TK, Radny, P, Zelba, H et al. (2010). High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116: 4139-4146.
40. Noguchi, S, Iwasaki, J, Kumazaki, M, Mori, T, Maruo, K, Sakai, H et al. (2013). Chemically modifed synthetic microRNA-205 inhibits the growth of melanoma cells in vitro and in vivo. Mol Ther 21: 1204-1211.
41. Dar, AA, Zaika, A, Piazuelo, MB, Correa, P, Koyama, T, Belkhiri, A et al. (2008). Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 112: 1688-1698.